Universität zu Köln

Abken, Hinrich (2017). Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. Hum. Gene Ther., 28 (11). S. 1047 - 1061. NEW ROCHELLE: MARY ANN LIEBERT, INC. ISSN 1557-7422

Full text not available from this repository.

Abstract

Adoptive therapy with chimeric antigen receptor (CAR) redirected T cells achieved lasting remissions in hematologic malignancies, even in terminal stages of the disease. Exploring CAR T cell therapy in the treatment of solid tumors has just begun, balancing efficacy versus toxicity in early phase trials. In contrast to leukemia/lymphoma, solid tumors display a tremendously variable biology demanding different strategies to make a T cell attack successful in the long term. This article summarizes current developments, discusses the hurdles, and considers some modifications to improve the CAR T cell therapy in the treatment of solid tumors.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Abken, Hinrich UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-212838
DOI:	10.1089/hum.2017.115
Journal or Publication Title:	Hum. Gene Ther.
Volume:	28
Number:	11
Page Range:	S. 1047 - 1061
Date:	2017
Publisher:	MARY ANN LIEBERT, INC
Place of Publication:	NEW ROCHELLE
ISSN:	1557-7422
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHIMERIC ANTIGEN RECEPTORS; I CLINICAL-TRIAL; PHASE-I; ANTITUMOR-ACTIVITY; CD28 COSTIMULATION; RECOMBINANT IMMUNORECEPTORS; ESTABLISHED TUMORS; IMMUNOTHERAPY; EFFICACY; RECOGNITION Multiple languages Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/21283